We have found 20 results when searching "Upadacitinib"
East Region Formulary ERFC Minutes 13 December 2023 Page 1 of 18 East Region Formulary Committee Minutes Date: 13 December 2023 Time: 2.00pm – 4.51pm Location: MS Teams Present: Alison Casey S...
East Region Formulary ERFC Minutes 07 August 2024 Page 1 of 19 East Region Formulary Committee Minutes Date: 07 August 2024 Time: 2.00pm – 4.45pm Location: MS Teams Present: Carla Capaldi ...
SMC2480 : For the treatment of active ankylosing spondylitis (AS) in adult patients who have responded inadequately to conventional therapy.
SMC2510 : For the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response, lost response or were intolerant to either conventional therapy...
SMC2495 : For the treatment of moderate to severe active rheumatoid arthritis (RA) in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rhe...
SMC2532 : For the treatment of active non-radiographic axial spondyloarthritis in adult patients with objective signs of inflammation as indicated by elevated C-reactive protein (CRP) and/or magnetic ...
SMC2575 : For the treatment of adult patients with moderately to severely active Crohn’s disease (CD) who have had an inadequate response, lost response or were intolerant to either conventional thera...
SMC2315 : For treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic dr...
SMC2361 : For the treatment of active psoriatic arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more DMARDs. Upadacitinib may be used as monotherapy or ...
SMC2417 : For the treatment of moderate to severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy. SMC restriction: patients who have had an inad...
